Salute e Benessere

Proteomics Market to Reach $161.9 billion, Globally, by 2035 at 14.2% CAGR…

Prime determinants of growth Prime determinants of growth Proteomics focuses on the comprehensive analysis of proteins within a biological system. Unlike genomics, which examines the entirety of an organism's genetic material, proteomics delves into the intricate world of proteins, the functional workhorses of cells. It involves the large-scale study of the structure, function, and interactions of proteins, aiming to understand their roles in biological processes and disease states...
PR Newswire
11/06/2024

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

STADA assumes marketing license for Alvotech's proposed biosimilar referencing Prolia ® /Xgeva ®(denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle EastThis partnership for the osteoporosis and cancer-related molecule builds on the two company's existing strategic alliance in Europe. The first product launched through the alliance was Hukyndra ®, a high-concentration biosimilar to Humira ®(adalimumab) Extended...
Nasdaq GlobeNewswire
11/06/2024

HKBU-led research predicts humidity trends will result in widespread heat stress…

Humidity determines heat stress difference Humidity determines heat stress difference Apart from heat, humidity also determines the extent of heat stress felt by humans because it affects our ability to control our body temperature by sweating. InChina, while heat stress is recorded in different parts of the country in summer, the relatively humid weather in the south is believed to have resulted in more frequent occurrence of heat stress with severe health and economic impacts...
PR Newswire
11/06/2024

GN to gradually wind-down its Elite and Talk product lines. Strong performance…

As communicated at the Capital Market Day in May 2024, GN is striving to build leading businesses in attractive markets and by this grow with healthy margins and ensure good returns on the invested capital.The re-focusing of the Elite product line towards the premium segment, which was initiated in 2023, has resulted in a stronger profitability level than before. However, the investment required for future innovation and growth in this very competitive space is deemed unjustified in the...
Nasdaq GlobeNewswire
11/06/2024

Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its…

The study enrolled 10 patients, all of whom suffered from severe disabling pain with Disability Ratings of 70% and higher. Following the procedure, typically lasting less than 20 minutes, all the patients saw maximal pain reduction with Disability Ratings reduced to 10% or less and they were able to walk freely without disability at discharge. The study enrolled 10 patients, all of whom suffered from severe disabling pain with Disability Ratings of 70% and higher. Following the procedure,...
PR Newswire
11/06/2024

Essential Pharma reaches agreement with AGC Biologics for late phase clinical…

Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastomaEgham, UK and Copenhagen, Denmark – 11 June, 2024– Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announced its rare disease business has...
Nasdaq GlobeNewswire
11/06/2024

Ultimovacs provides update from Phase I study in malignant melanoma: Continued…

All patients in the trial who were alive at 3 years remain alive at 4 years (69.5%) with a minimum follow-up period of 4 years (median 53.0 months)The expected next key milestone for UV1 is the readout of the FOCUS trial during Q3 2024, in which the treatment combination is the same as in the UV1-103 trialOslo, June 11, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced encouraging overall...
Nasdaq GlobeNewswire
11/06/2024

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis…

NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis PatientsAarhus, Denmark, 11 June 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces today that it has dosed the first generalized myasthenia gravis (gMG) patient in a Phase 2b clinical trial of NMD670, after receivingFDA IND clearance in March 2024to conduct the study. The first US patient...
Nasdaq GlobeNewswire
11/06/2024

Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by…

Key Takeaways from the Postherpetic Neuralgia Market Report Key Takeaways from the Postherpetic Neuralgia Market Report Discover which therapies are expected to grab the major postherpetic neuralgia market share @ Postherpetic Neuralgia Market Report Postherpetic Neuralgia Overview Postherpetic neuralgia is a frequent complication of shingles, which arises from the reactivation of the varicella-zoster virus (VZV) that remains dormant in the body after an initial varicella infection...
PR Newswire
10/06/2024

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of…

Ipsen's Iqirvo ®(elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC)First-ever drug developed in-house by GENFIT to achieve U.S. FDA's approvalGENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20% Lille (France), Cambridge (Massachusetts, United States), Zurich...
Nasdaq GlobeNewswire
10/06/2024

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR…

Iqirvo ®(elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial dataPrimary biliary cholangitis impacts approximately 100,000 people in the US and is growing in global prevalence. If inadequately treated, it can cause liver failureU.S...
Nasdaq GlobeNewswire
10/06/2024

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661…

LRP-661's data highlights its superior safety, efficacy, bioavailability, and PK in multiple species. Furthermore, LRP-661's oral formulation ability compared to cannabidiol, marks a significant advancement in the field of epilepsy treatment. Notably, the compound demonstrates exceptional efficacy in PTZ fully kindled mice, Maximal Electroshock Seizure (MES), MES Threshold, and pentylenetetrazol (PTZ)–induced seizure data.When compared against the currently available oral solution of...
Nasdaq GlobeNewswire
10/06/2024

Medical Virtual Assistant Market Size to Grow USD 2668.4 Million by 2029 at a…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19Y16064/Global_Medical_Virtual_Assistant_Market Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19Y16064/Global_Medical_Virtual_Assistant_Market Major Factors driving the growth of Medical Virtual Assistant market: The growing desire for individualized patient experiences, affordable healthcare solutions, and the expanding use of AI and machine learning technologies in the healthcare...
PR Newswire
10/06/2024

Partnership of Spineway with the SFCR for June 24 congress

Press release Ecully, June 10, 2024 – 6 p.m. SPINEWAY partners with the Société Française de Chirurgie du Rachis (SFCR) Congress in Montpellier, France The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it will be a partner of the Société Française de Chirurgie du Rachis (SFCR) Congress, one of the most important spine surgery events in France. The new edition will be held from June 13 to 15, 2024 at the Corum...
Nasdaq GlobeNewswire
10/06/2024

Hormone Replacement Therapy Market Size to Grow USD 18280 Million by 2030 at a…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19G13044/Global_Hormone_Replacement_Therapy_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-19G13044/Global_Hormone_Replacement_Therapy_Market Major Factors Driving the Growth of Hormone Replacement Therapy Market: The need for effective treatment methods, such as hormone replacement therapy (HRT), has increased due to the rising prevalence of menopausal symptoms among aging...
PR Newswire
10/06/2024

Drug Discovery Informatics Market Size to Grow USD 1 Million by 2030 at a CAGR…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-14V4103/Global_Drug_Discovery_Informatics_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-14V4103/Global_Drug_Discovery_Informatics_Market Major Factors Driving the Growth of Drug Discovery Informatics Market: The desire for tailored treatment, growing investment in pharmaceutical R&D, and technological improvements are the main factors driving the growth of the Drug Discovery...
PR Newswire
10/06/2024

Chlorella Market to Reach $639.7 Million by 2031 - Exclusive Report by…

Chlorella is a genus of green algae that have a spherical shape. The cultivation of chlorella involves relatively limited resources. Some of the main applications of the genus Chlorella are in biofuels (biodiesel, biomethane, and biohydrogen), cosmetics (skincare), supplementary foods (polyunsaturated fatty acids), pigments (carotenoids and chlorophyll), and waste-water treatments (reduction of chemical oxygen demand and bioremediation). Chlorella is a genus of green algae that have a spherical…
PR Newswire
10/06/2024

Medical Laser Market to Be Worth $17.3 Billion by 2031 - Exclusive Report by…

Medical lasers are devices that use precisely focused light sources for treating or removing tissues. Since lasers can focus accurately on tiny areas, they are used for precise surgical works or for cutting through tissue in place of a scalpel. Lasers are commonly employed in many medical disciplines, including dermatology, dentistry, cardiology, neurosurgery, and eye surgery, because of their ability to deliver high-precision treatments while remaining minimally invasive. Laser-based therapies…
PR Newswire
10/06/2024

Dural Adhesive Agent for the Surgical Market Worth USD 263.2 Million by 2031 -…

Dural adhesive agents for the surgical market are experiencing significant growth, propelled by the increasing prevalence of neurological disorders, the growing aging population, and technological advancements in neurosurgical techniques. The dural adhesive agent for the surgical market is focused on products used to seal and repair the dura mater. The increasing occurrence of neurological disorders and the rising number of neurosurgeries globally drive the market. Dural adhesive agents for…
PR Newswire
10/06/2024

Exosome Diagnostics and Therapeutics Market Surges, Anticipated to Hit USD 6,848…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198025144 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198025144 Browse in-depth TOC on "Exosome Diagnostics and Therapeutics Market" 335 - Tables45 - Figures250 - Pages Exosome Diagnostics Segment Leads Market Share in 2023 In 2023, the exosome diagnostics segment emerged as the frontrunner in market share, underscoring its pivotal role in driving...
PR Newswire
10/06/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from June 3, 2024, to June 7, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
10/06/2024

Cell & Gene Therapy Supply Chain Software Market Expected to Grow at a 13.9%…

Enhanced therapies, including cell and gene therapy products, have reformed healthcare practices. The prevalence of such therapeutic options has led to an uprise shift in modern medicine's development, production, and consumption. Moreover, such therapies have established healthcare providers to treat several rare clinical conditions. Enhanced therapies, including cell and gene therapy products, have reformed healthcare practices. The prevalence of such therapeutic options has led to an…
PR Newswire
10/06/2024

Cell and Gene Therapy CRO Market Review Report 2024-2031 | Latest by InsightAce…

Gene therapies are a type of medicine that has the potential to treat many different ailments. Whereas conventional medicine focuses on alleviating symptoms, their strategy is to deal with the sources of ailments. Also, they have the potential to help with a wide variety of ailments that have not responded to other treatments, including those involving the eyes, the nervous system, and cancer. One approach to gene therapy that makes use of viral vectors is the delivery of therapeutic genes to…
PR Newswire
10/06/2024

Smartee Successfully Hosts GS Mandibular Repositioning Conference in Spain

Professor Shen highlighted the challenges of severe malocclusions with skeletal components in the current orthodontic world. He emphasized that severe Class II jaw discrepancies, often caused by maxillary overgrowth and mandibular retrusion, result in a prognathic facial profile and malocclusion characterized by increased overjet, overbite, and a deep curve of Spee. One crucial treatment modality for this condition is the forward repositioning of the mandible, leading to regional adaptive…
PR Newswire
10/06/2024
Altri  Comunicati